GAITHERSBURG, Md., Sept. 7, 2022 /PRNewswire/ -- Novavax, Inc. ( Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Read more at prnewswire.com
Novavax to Participate in Upcoming September Conferences
Provided By PR Newswire – Last update: